Skip to main content

Table 2 Pfmdr1 copy number (CN) among subclinical and clinical isolates from three regions of Myanmar 2008–2009

From: Molecular surveillance for drug-resistant Plasmodium falciparum in clinical and subclinical populations from three border regions of Burma/Myanmar: cross-sectional data and a systematic review of resistance studies

  pfmdr1 CN % CN >1.5
  1 2 3 4 (95% CI)a OR (95% CI)a
Karen State (n = 40) 33 6 0 1 17.5 (0–54.3)  
Clinic 21 0 0 0 0.0  
Screening 12 6 0 1 35.0 n/a
Kachin State (n = 18) 16 2 0 0 9.6 (0–31.6)  
Clinic 5 1 0 0 16.7  
Screening 11 1 0 0 8.3 0.5 (0.0–7.8)b
Chin-Mizoram (n = 115) 104 11 0 0 11.1 (0–32.1)  
Clinic 76 6 0 0 7.3  
Screening 28 5 0 0 15.2 2.3 (1.1-4.7)b
Screening vs clinicalTotal (n = 173) 153 19 0 1 11.6 (2.7-20.4)  
Clinic 102 7 0 0 6.4  
Screening 51 12 0 1 20.3 3.7 (1.1-12.5)b
Anti-malarial treatment Total (n = 168) 148 20 0 1   
No treatment in past 8 weeks 117 17 0 1 12.7  
Treatment in past 8 wks 31 3 0 0 8.8 0.7 (0.1-3.1)c
  1. aCIs adjusted for clustering within study site (n = 13).
  2. bOR = odds of pfmdr1 amplification among screening participants/odds of amplification among febrile clinical patients.
  3. c OR = odds among participants reporting treatment in past 8 weeks/odds among those not reporting treatment in previous eight weeks.